{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T20:18:07Z","timestamp":1767212287338,"version":"3.37.3"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T00:00:00Z","timestamp":1704758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020437","name":"Beijing Association for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020437","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.eclinm.2024.102431","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T22:34:06Z","timestamp":1706222046000},"page":"102431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3975-9853","authenticated-orcid":false,"given":"Li","family":"Bao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Tong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Qiu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong-Jun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He-Bing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Rong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eclinm.2024.102431_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"year":"2014","series-title":"SEER cancer statistics review, 1975-2007","author":"Altekruse","key":"10.1016\/j.eclinm.2024.102431_bib2"},{"issue":"13","key":"10.1016\/j.eclinm.2024.102431_bib3","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"year":"2021","series-title":"Multiple myeloma(version 1.2022). NCCN clinical practice guidelines in Oncology (NCCN Guidelines\u00ae)","author":"Shaji","key":"10.1016\/j.eclinm.2024.102431_bib4"},{"key":"10.1016\/j.eclinm.2024.102431_bib5","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.12659\/MSM.907588","article-title":"Real-world clinical outcomes in elderly Chinese patients with multiple myeloma: a single-center experience","volume":"24","author":"Qian","year":"2018","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102431_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262388","article-title":"Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients","volume":"17","author":"Djebbari","year":"2022","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.eclinm.2024.102431_bib7","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.20.03143","article-title":"Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the Hovon 143 study","volume":"39","author":"Stege","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102431_bib8","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102431_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056147","article-title":"Frailty-adjusted therapy in transplant Non-Eligible patients with newly diagnosed multiple myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial","volume":"12","author":"Coulson","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102431_bib10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","article-title":"Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA","volume":"36","author":"Facon","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102431_bib11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.clml.2021.06.005","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE","volume":"21","author":"Mateos","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"10.1016\/j.eclinm.2024.102431_bib12","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2024.102431_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.597453","article-title":"Pegylated liposomal doxorubicin in vindesine-based and bortezomib-based regimens for patients with newly diagnosed multiple myeloma: a retrospective study of efficacy and safety","volume":"11","author":"Zhai","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102431_bib14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13231","article-title":"Ixazomib maintenance therapy in newly diagnosed multiple myeloma: an integrated analysis of four phase I\/II studies","volume":"102","author":"Dimopoulos","year":"2019","journal-title":"Eur J Haematol"},{"issue":"34","key":"10.1016\/j.eclinm.2024.102431_bib15","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102431_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102431_bib17","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"year":"2009","series-title":"Common terminology criteria for adverse events (CTCAE) version 4.0","key":"10.1016\/j.eclinm.2024.102431_bib18"},{"key":"10.1016\/j.eclinm.2024.102431_bib19","series-title":"Encyclopedia of quality of life and well-being research","first-page":"1933","article-title":"Eortc QLQ-C30","author":"Sprangers","year":"2014"},{"year":"2011","series-title":"Design and analysis of non-inferiority trials","author":"Rothmann","key":"10.1016\/j.eclinm.2024.102431_bib20"},{"issue":"Supplement 2","key":"10.1016\/j.eclinm.2024.102431_bib21","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S2152-2650(21)02287-4","article-title":"Efficacy and safety of induction therapy with IAd versus IRd regimen in fragile elderly patients with newly diagnosed multiple myeloma: results of a prospective multicenter clinical trail","volume":"21","author":"Bao","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuke"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102431_bib22","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/10428194.2023.2189989","article-title":"Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data","volume":"64","author":"Su","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102431_bib23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3324\/haematol.2021.280394","article-title":"All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study","volume":"107","author":"Touzeau","year":"2022","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102431_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41408-021-00590-5","article-title":"Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial","volume":"11","author":"Mina","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102431_bib25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102431_bib26","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10218","key":"10.1016\/j.eclinm.2024.102431_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102431_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/hematolrep15010015","article-title":"Frail multiple myeloma patients deserve more than just a score","volume":"15","author":"Miller","year":"2023","journal-title":"Hematol Rep"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102431_bib29","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2024.102431_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jconrel.2020.04.018","article-title":"Design principles of drug combinations for chemotherapy","volume":"323","author":"Wu","year":"2020","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.eclinm.2024.102431_bib31","first-page":"44","article-title":"Efficacy and safety of ixazomib induction and maintenance in newly diagnosed multiple myeloma patients according to the IMWG frailty score: a post-hoc analysis of the EMN10-Unito trial","volume":"136","author":"Mina","year":"2020"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T23:11:00Z","timestamp":1728601860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":31,"alternative-id":["S2589537024000105"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102431","relation":{},"ISSN":["2589-5370"],"issn-type":[{"type":"print","value":"2589-5370"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102431"}}